Table 1

Study characteristics

All patientsRAPMRIBDLow-doseMedium-doseShort follow-upLong follow-up
Studies (N)28 (3780)14 (1708)4 (167)10 (1905)17* (2184)13* (1596)14 (1762)14 (2018)
GC-using populations (N)39 (2382)17 (796)6 (167)16 (1419)23 (1398)16 (984)21 (1362)18 (1020)
Age (years)4654723747443952
Gender (% female)6370695564615668
Mean (SD) dose prednisone equivalent (mg)11.5 (14.5)7.5 (5.9)8.6 (3.2)13.9 (13)6.7 (4.8)18.0 (20)14.6 (17.4)7.2 (4.8)
Quality analysis of the (sub)populations of the included studies
AE scoring per protocol (N)22 (2960)10 (1047)3 (142)9 (1771)15 (1817)9 (1143)11 (1470)11 (1490)
Mean time AE scoring (months)1.73.41.40.92.21.00.53
Predefined AE (N)15 (1976)9 (1072)3 (142)3 (762)10 (1438)5 (538)5 (578)10 (1398)
Number of predefined AE7.98.85.87.08.36.86.28.6
Missing data (N)†24 (3471)11 (1424)3 (142)10 (1905)14 (1900)12 (1571)12 (1702)12 (1769)
Missing data (%)‡21.319.823.921.722.120.12219.7
  • *Two studies (Sandborn, 1998; Rutgeers, 1994) were split into two subpopulations as they included both low- and medium-dose populations.

  • †Missing data: number of studies which noted patients who dropped out of the study.

  • ‡Percentage of patients of the study population who dropped out of the study.

  • N, number of studies/populations (number of patients); IBD, inflammatory bowel disease; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis.

  • Low dose: ⩽7.5 mg prednisolone equivalent; medium dose: >7.5 mg and ⩽30 mg prednisolone equivalent; short follow-up: study duration ⩽6 months; long follow-up: study duration >6 months.